Avenue Therapeutics Inc (NASDAQ:ATXI) – Equities researchers at Oppenheimer raised their Q1 2019 earnings estimates for shares of Avenue Therapeutics in a research report issued to clients and investors on Wednesday, March 13th. Oppenheimer analyst L. Gershell now anticipates that the company will earn ($0.46) per share for the quarter, up from their previous forecast of ($0.53). Oppenheimer also issued estimates for Avenue Therapeutics’ Q2 2019 earnings at ($0.65) EPS and FY2019 earnings at ($1.54) EPS.

Separately, ValuEngine upgraded shares of Avenue Therapeutics from a “hold” rating to a “buy” rating in a report on Monday, February 4th.

ATXI stock opened at $5.82 on Monday. Avenue Therapeutics has a 52-week low of $2.08 and a 52-week high of $6.82. The company has a market cap of $62.53 million, a PE ratio of -2.77 and a beta of -0.82.

Several hedge funds have recently added to or reduced their stakes in the company. National Asset Management Inc. raised its holdings in shares of Avenue Therapeutics by 4.7% during the fourth quarter. National Asset Management Inc. now owns 66,250 shares of the company’s stock valued at $358,000 after acquiring an additional 3,000 shares during the period. Northern Trust Corp acquired a new stake in shares of Avenue Therapeutics during the fourth quarter valued at approximately $79,000. Finally, Opaleye Management Inc. acquired a new stake in shares of Avenue Therapeutics during the fourth quarter valued at approximately $2,678,000. Institutional investors and hedge funds own 6.46% of the company’s stock.

In other news, Director Neil Herskowitz purchased 5,000 shares of the business’s stock in a transaction dated Monday, February 25th. The shares were acquired at an average price of $5.46 per share, for a total transaction of $27,300.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders have bought 15,947 shares of company stock worth $91,630 in the last 90 days. 5.00% of the stock is owned by company insiders.

Avenue Therapeutics Company Profile

Avenue Therapeutics, Inc, a specialty pharmaceutical company, acquires, licenses, develops, and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, which is in Phase III clinical trials to treat moderate to moderately severe post-operative pain.

Further Reading: How to use beta for portfolio diversification

Receive News & Ratings for Avenue Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avenue Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.